Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
High Conviction Trades
Discover high conviction trades that caused a significant change in a fund's stake in a stock
Fund Manager Portfolios
Gain insights from the world’s largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Search
Sign in
Sign up
Amneal Pharmaceuticals
AMRX
Market cap
$4.2B
Overview
Fund Trends
Analyst Outlook
Journalist POV
13.17
USD
+0.22
1.7%
At close
Updated
May 29, 4:00 PM EDT
Pre-market
After hours
13.10
-0.07
0.53%
1D
5D
1M
3M
6M
YTD
1Y
5Y
10Y
1 day
1.7%
5 days
5.7%
1 month
2.89%
3 months
-4.36%
6 months
6.99%
Year to date
4.03%
1 year
80.41%
5 years
131.46%
10 years
-12.26%
Upgrade to unlock
Positive
Neutral
Negative
Sentiment
3-Months
Positive
Neutral
36.8%
Negative
Positive
Neutral
Negative
Positive
Zacks Investment Research
5 days ago
Is it a Good Idea to Invest in Amneal Pharmaceuticals Stock Now?
AMRX is building momentum with growth across specialty drugs and biosimilars, supported by new launches and a diversified portfolio.
Positive
Zacks Investment Research
13 days ago
Why Amneal Pharmaceuticals (AMRX) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
Zacks Investment Research
16 days ago
3 Reasons Why Growth Investors Shouldn't Overlook Amneal (AMRX)
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Positive
Zacks Investment Research
16 days ago
Should Value Investors Buy Amneal Pharmaceuticals (AMRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Zacks Investment Research
23 days ago
Amneal (AMRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Revised)
Although the revenue and EPS for Amneal (AMRX) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neutral
GlobeNewsWire
24 days ago
Amneal Reports First Quarter 2026 Financial Results
‒ Q1 2026 Net Revenue of $723 million ; GAAP Net Income of $62 million ; Diluted Income per Share of $0.19 ‒ ‒ Adjusted EBITDA of $202 million ; Adjusted Diluted EPS of $0.27 ‒ ‒ No Change from Preliminary Results Previously Announced on April 22, 2026 ‒ ‒ Affirms Previously Announced Increase in 2026 Full Year Guidance ‒
Positive
Zacks Investment Research
1 month ago
Is Amneal (AMRX) a Solid Growth Stock? 3 Reasons to Think "Yes"
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 34.77% Upside in Amneal (AMRX): Can the Stock Really Move This High?
The consensus price target hints at a 34.8% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Positive
Zacks Investment Research
1 month ago
Amneal Pharmaceuticals (AMRX) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
1 month ago
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Show more
See News Rankings
Sign up
Sign in
Fund Insights
Common Fund Bets
See what stocks and ETFs funds are collectively bullish/bearish on
Largest Fund Trades
Explore the largest stock and ETF buys and sells made by funds
High Conviction Trades
Discover high conviction trades that caused a significant change in a fund's stake in a stock
Fund Manager Portfolios
Gain insights from the world’s largest funds and super investors
Analyst Insights
Price Target Consensus
See what stocks research analysts are collectively bullish/bearish on
Latest Ratings Feed
Explore the latest ratings and price targets from the best equity research analysts
Equity Analyst Profiles
Browse analysts, their latest ratings and track record
Research Firm Profiles
Browse research firm recommendations, trends, and performance
WSR Indexes
Fund Manager Index
Stock index based on fund manager consensus updated each quarter
Analyst Index
COMING SOON - Stock index based on equity analyst consensus updated every second
Theme
Close